Vector Science & Therapeutics授出20.6万份期权持续推进增长战略

环球市场播报06-02

Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。　　根据公告，此次授予的期权将根据公司股票期权计划在2026年剩余时间内分批归属，有效期为自授予之日起五年。此次期权授予尚需获得多伦多证券交易所创业板的批准。公司期权计划为10%...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640492479?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-02 22:39","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2640492479","market":"other","top_or_hot":-1,"title":"Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略","media":"环球市场播报","content":"<div>\n<p>Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。\n　　根据公告，此次授予的期权将根据公司股票期权计划在2026年剩余时间内分批归属，有效期为自授予之日起五年。此次期权授予尚需获得多伦多证券交易所创业板的批准。公司期权计划为10%...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVector Science & Therapeutics授出20.6万份期权 持续推进增长战略\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-02 22:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。\n　　根据公告，此次授予的期权将根据公司股票期权计划在2026年剩余时间内分批归属，有效期为自授予之日起五年。此次期权授予尚需获得多伦多证券交易所创业板的批准。公司期权计划为10%...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumk4647843.shtml","article_id":"2640492479","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640492479","pubTimestamp":1780411140,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。此次期权授予尚需获得多伦多证券交易所创业板的批准。　　公司于今年4月完成在多伦多证券交易所创业板的上市，股票代码PAIN，为这一增长战略的推进提供了资本市场支持。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BK4561":"索罗斯持仓","BK4539":"次新股","LENZ":"Therapeutics","VAQC":"Vector Acquisition Corporation II","BK4007":"制药"},"translate_title":"Vector Science & Therapeutics 206,000 options granted to continue to advance growth strategy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VAQC":1.5,"LENZ":1.5},"content_text":"Vector Science & Therapeutics Corp．周二宣布，公司董事会已批准向部分董事授予206，610份股票期权，行权价为每股1.69加元。此举正值公司近期完成多项战略布局、加速推进增长战略之际。\n　　根据公告，此次授予的期权将根据公司股票期权计划在2026年剩余时间内分批归属，有效期为自授予之日起五年。此次期权授予尚需获得多伦多证券交易所创业板的批准。公司期权计划为10%滚动计划，目前共预留6，556，610股普通股供发行，剩余可发行期权数量为8，792，446份。\n　　此次期权授予正值公司多项关键战略举措积极推进之际。本月早些时候，公司宣布与MPP集团签署为期三年的开发与制造协议，将化合物配方、分析测试及Vector的专利透皮递送平台整合于同一FDA注册的cGMP合规设施内，加速开发周期，确保从配方到递送的质量。该安排支持公司以制药级、室温稳定型制剂进入估值808亿美元的肽类药物市场。根据协议，公司为肽类药物生产设备提供资金并保留所有权。\n　　此外，公司上月宣布已提交一项临时专利申请，涵盖一种用于肿瘤内药物递送研究的新型导管平台，初步科学聚焦于胰腺癌。该平台整合三种研究模式：细胞分化剂的肿瘤内递送、基于肿瘤组织电导率差异的电消融以及电导化疗激活。\n　　公司于今年4月完成在多伦多证券交易所创业板的上市，股票代码PAIN，为这一增长战略的推进提供了资本市场支持。公司总部位于威斯康星州Mequon，专注于开发新型生物力学器械和主动局部药物递送平台，为临床医生提供精准、低系统风险的靶向干预方案。\n\n新浪合作大平台期货开户 安全快捷有保障\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640492479","isCrawlerRequest":true}

Vector Science & Therapeutics授出20.6万份期权 持续推进增长战略

精彩评论

Vector Science & Therapeutics授出20.6万份期权持续推进增长战略